FRONTKEN CORPORATION BERHAD 200401012517 (651020-T) ANNUAL REPORT 2025 158 NOTICE OF TWENTY-SECOND ANNUAL GENERAL MEETING (CONT’D) Explanatory Notes on Ordinary Business: 1. Item 1 of the Agenda This Agenda item is meant for discussion only as the provision of Section 340(1)(a) of the Act does not require a formal approval of the shareholders for the Audited Financial Statements. Hence, this item is not put forward to shareholders for voting. 2. Item 2 of the Agenda The Nomination Committee has evaluated Dr Tay Kiang Meng and YM Raja Jastina Adlina Binti Raja Arshad based on the Board Effectiveness Evaluation including the “Fit and Proper Test” to assess them and they were found to have met the Board’s expectation in discharging their duties and responsibilities and recommended to the Board for their re-election. In turn, the Board recommends to the shareholders to re-elect Dr Tay Kiang Meng and YM Raja Jastina Adlina Binti Raja Arshad at the 22nd AGM or any adjournment thereof. 3. Item 3 of the Agenda Section 230(1) of the Act requires that the fees of the directors and any benefits payable to the directors be approved at a general meeting. Explanatory Notes on Special Business: 4. Item 5 of the Agenda The proposed Ordinary Resolution 5, if passed, will empower the Directors from the conclusion of this AGM, to allot and issue up to a maximum of 10% of the total number of issued shares of the Company (excluding treasury shares) at the time of issue (other than bonus or rights issue) until the conclusion of the next AGM of the Company without the need to convene a general meeting and for such purposes as they consider would be in the best interest of the Company. This authority, unless revoked or varied at a general meeting, will expire at the conclusion of next the AGM of the Company. The Board is of the view that the 10% general mandate is in the best interest of the Company and its shareholders as it would provide the flexibility to the Company for any possible fundraising activities that the Company may undertake for working capital and/or any investment or acquisition purposes in an expeditious and efficient manner. At this juncture, there is no decision to issue any additional shares. If there should be a decision to issue any new share after the general mandate is sought, the Company will make an announcement in respect thereof. The proposed Ordinary Resolution 5 is a renewal of the general mandate for issuance of shares pursuant to Sections 75 and 76 of the Act obtained at the 21st AGM held on 12 June 2025 which will lapse at the conclusion of this 22nd AGM. As at the date of this notice, the Company did not issue any share pursuant to the said general mandate. 5. Item 6 of the Agenda The proposed Ordinary Resolution 6, if passed, will give the Directors of the Company the authority to take all such steps as are necessary or expedient to implement, finalise, complete and/or effect the purchase(s) of Shares by the Company as the Directors may deem fit and expedient in the best interest of the Company. This authority will, unless renewed or revoked or varied by the Company at a general meeting, continue to be in force until the conclusion of the next AGM or any adjournment thereof of the Company or the expiry of the period within which the next AGM of the Company following the 22nd AGM is required by the law to be held. Please refer to the Share Buy-Back Statement dated 29 April 2026 which is circulated together with this Notice for more information.
RkJQdWJsaXNoZXIy NDgzMzc=